https://www.avient.com/sites/default/files/2023-02/AVNT Q4 2022 Earnings Presentation.pdf
Microsoft PowerPoint - AVNT Q4 2022 Earnings Presentation AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 2 R E S U L T S A N D 2 0 2 3 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A R Y 1 5 , 2 0 2 3 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. EPS (1) $0.14 $2.67 $3.04 2006 2018 2022PF TO P- TI E R S U S TA I N A B I L I T Y P E R F O R M A NC E A N D R E C O G N I T I O N Industry Sustainability Standards 90th percentile 84th ESG Ratings Performance 3 1 4 10 PEOPL E C U L T U R E I S E V E R Y T H I N G Community Service 7x Safer than Industry Average World-Class Safety Leadership Development Over $17 million raised since 2010 Diversity & Inclusion 11 2 0 2 2 R E S U L T S Q4 EBITDA BRIDGE ( P R O F O R M A T O TA L C O M PA N Y ) 13 $ millions CAI: Price / Mix 42 Inflation (20) SEM: Price / Mix 14 Inflation (10) Net Price Benefit 26 Wage and Energy Inflation (13) Clariant Color Integration Synergies 4 Incentives, Other Employee Costs 21 FX (10) Q4 2022 $107 Adjusted EBITDA Q4 2021 $ 132 Demand (50) Russia Import Sales (3) • Demand contraction especially prevalent in EMEA and Asia • Pricing continues to cover inflation of raw materials, wages and energy P ROV E N T R AC K R E C O R D O F S T RO N G A N D I M P ROV I N G F R E E C A S H F LOW G E N E R AT I O N 14 • Periods of economic weakness have driven higher levels of cash generation due to working capital management • Anticipate continued strong free cash flow generation and conversion despite global uncertainty 78% 78% 80% 80% 81% 78% 84% 83% 80% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 2014 2015 2016 2017 2018 2019 2020 2021 2022 0 50 100 150 200 250 300 350 400 F re e C a s h F lo w C o n v e rs io n F re e C a s h F lo w FCF $ AVNT FCF Conversion % S&P FCF Conversion % Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA. 2020 is pro forma for Clariant Color and 2022 is pro forma for Avient Protective Materials Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 28 79 87 81 79 76 73 90 77 76 75 73 64 59 33 A vi e n t K W R P P G F U L A V Y R P M F M C C E A S H H X L E C L H U N E M N S C L M U LT I P L E E X PA N S I O N Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of 2023年2月13日 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89.
https://www.avient.com/sites/default/files/2023-03/Cesa Fiber Additives for Heat Preservation Technical Bulletin_TW.pdf
Cesa Fiber Additives for Heat Preservation Technical Bulletin_TW2.28-1 Cesa™ 紅外蓄熱纖維添加劑 熱影像圖片 加熱前表面溫度:20.22°C 技術公告 埃萬特推出新一代應用於紡織纖維的紅外蓄熱添加 劑配方,旨在幫助品牌商能夠更加輕鬆地滿足消費 者對冬裝、運動裝和床上用品輕量舒適的要求。• • • 測試方法:FTTS-FA-010-2007 4.2 設備:紅外線熱像儀 熱源:500W鹵素燈 熱輻射距離:100 cm 加入Cesa紅外蓄熱纖維添加劑 加熱10分鐘後表面溫度:33.85°C 溫度變化:+13.6°C 測試方法 0.9 9°C 8.9°C 5.6°C 0.625 +12.9% +13.6% +1.7% www.avient.com 標準要求 測試結果 GB/T 30127 遠紅外線性能 GB/T 18319-2019 光蓄熱性能 FTTS-FA-010 紅外線性能及蓄熱升溫 GB/T 11048-2008 Method A 熱舒適性 熱阻性能 單位:CLO 人體生理實驗 遠紅外線發射率 ≥0.88 (5-14um) (測試溫度:34°C) 遠紅外線輻射溫升值 ≥1.4°C 最高允許溫升值 ≥6°C 平均溫升值 ≥4.4°C(20分鐘) 平均發射率 ≥ 0.8 (2-22um) (測試溫度: 25°C) 0.81 規定加熱ΔT ≥ 0.5°C (相對於標準) +5.34°C (ΔT) 裸體:0 內褲:0.04 T恤:0.09 厚毛衣:0.35 冬季大衣:0.7 上述所有資料均為參考值 血流量 血流速 血氧濃度(%SpO2) 請聯絡您的埃萬特業務代表以了解 您所在國家或地區是否有售。
https://www.avient.com/sites/default/files/2021-03/avient-march-ir-fermium_0.pdf
W H AT W E D O : M AT E R I A L S C I E N C E 5 CUSTOM FORMULATION We sell solutions not commodities. D is t. ) K W R R P M P P G A V Y F U L G C P F M C H X L IF F F O E H U N E C L K R A E M N A S H C E S C L G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of 2021年3月12日 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of 2021年3月12日 85 89 86 86 82 80 76 89 85 83 82 81 78 77 77 76 75 73 70 69 49 19 A vi e n t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H B N R F O E E M N C E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of 2021年3月12日 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is below specialty formulator peers and some of our more highly valued chemical peers.
https://www.avient.com/sites/default/files/2022-03/AVNT Mar 2022 Presentation.pdf
W H AT W E D O : M AT E R I A L S C I E N C E 4 CUSTOM FORMULATION We sell solutions not commodities. D is t. ) K W R P P G F U L R P M A V Y F M C H U N H X L S C L E C L E M N C E A S H Source: Peer data per Bloomberg market data as of 2022年2月15日. O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 5.4 8.5 10.1 10.0 15.7 15.0 14.2 12.7 10.2 25.0 19.7 17.7 13.2 12.3 10.0 9.9 8.9 8.5 8.3 6.6 A vi e n t (2 0 1 1 ) A vi e n t (2 0 1 6 ) A vi e n t (2 0 2 1 ) A vi e n t (T o d a y) R P M K W R P P G A V Y F U L A L B E C L H X L A S H F M C B N R E M N U N V R C E S C L H U N Historic Multiple S U M M A RY: W H Y I N V E S T I N AV I E N T ?
https://www.avient.com/sites/default/files/2022-12/Mevopur Healthcare Colorants and Formulations for Needle Hubs Application Bulletin.pdf
KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Color can be combined with additives to enhance performance and protection REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Device Master File • Food contact established with FDA/EU* NOMINAL OUTSIDE DIAMETER OF NEEDLE (MM) COLOR DESCRIPTION RAL PANTONE TRANSPARENT PRODUCT CODE OPAQUE PRODUCT CODE 0.4 Medium Grey 7035 423 C PP7M665125 PP7M665127 0.45 Brown 8017 7588 C PP8M665294 PP8M665296 0.5 Orange 2003 173 C PP2M665298 PP2M665300 0.55 Medium Purple 4005 7676 C PP4M665290 PP4M665292 0.6 Deep Blue 5010 288 C PP5M665894 PP5M665896 0.7 Black 9005 Black C PP9M664950 PP9M664952 0.8 Deep Green 6001 7483 C PP6M665687 PP6M665689 0.9 Yellow 1021 115 C PP1M665211 PP1M665213 1.1 Cream 1015 7401 C PP0M665290 PP0M665292 1.2 Pink 3015 502 C PE3M665725 PP3M665727 Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2023-12/_ECCOH LSFOH 5983 Formulations Product Bulletin.pdf
The ECCOH 5983 formulation has been developed to help prevent stress cracking in armored cables by offering high tear strength and elongation at break at temperatures ranging from -25°C to 90°C. MARKETS AND APPLICATIONS • Cable jackets for low and medium-voltage power cables with metal armoring, typically installed underground or where installation requires them to be bent • Armored cable applications that require compliance with LTS1 requirements as per the BS 7655-6.1 standard IMPACT • High environmental stress cracking resistance • High tear strength and elongation at break at temperatures ranging from -25°C to 90°C • Flame retardant performance • Limiting oxygen index (LOI) of 36% • Exceeds BS 7655-6.1:1997 standard criteria for LTS1–LTS4 for complex designs and armored cables PRODUCT BULLETIN Cable jacket liable to cracking Power Cable Cross Section Metal armoring 1.844.4AVIENT www.avient.com Copyright © 2023, Avient Corporation. KEY CHARACTERISTICS ECCOH 5924FORMULATION ECCOH 5981 FORMULATION ECCOH 5983 UV FORMULATION Material Standards BS7655-6, 1 (LTS1–4), BS6724, IEC 60502 BS7655-6, 1 (LTS3) BS7655-6, 1 (LTS1–4) Tear Strength at 23°C 7.7 N/mm 10 N/mm 11 N/mm Tear Strength at 65°C 2.3 N/mm 5 N/mm 6.5 N/mm Hot Pressure Test (6h at 90°C) 39% –
https://www.avient.com/sites/default/files/2020-11/syncure-xlpe-processing-guide.pdf
EXTRUDER Screw 1½" to 6" Polyethylene type—Maddock; 3:1 compression ratio Tooling Pressure type Die On size with 1/8" or less land L/D 24:1 or higher Screen Pack 20/60/60/20 Mesh Cooling Trough Hot 120–150° F (50–65° C) Feeder Gravimetric type—3 compartment (for color) Drying Conditions, Catalyst Only Desiccant type, 4 hours at 140° F (60° C) PROCESSING Temperature Wire Preheat 180–250° F (110–120° C) Feed Zones 330° F (165° C) Transition 340° F (170° C) Metering 350° F (177° C) Head/ Die 360° F (182° C) Target Melt 350–380° F (177–190°C) Flame at Die Tip Yes Line Speed Higher line speed improves mixing and surface smoothness Purge Compound HDPE To learn more about Syncure XLPE wire and cable solutions, contact us at +1.844.4AVIENT (1-844.428.4368) www.avient.com Copyright © 2020, Avient Corporation.
https://www.avient.com/sites/default/files/2021-09/mevopur-colors-for-ophthalmic-closures-application-bulletin-cn.pdf
法规支持 经过预测试的原材料:- ISO 10993-1 - USP 第、章(VI类) - USP (指南),6.2.3 可萃取元素; USP - ICHQ3D/USP 2 可萃取金属 - 欧洲药典 3.1 聚烯烃(如适用) FDA发布的注册药品管理档案(III类)和/或医 疗器械管理档案 食品接触符合FDA/EU*要求 • • • 主要特性 在三个通过ISO 13485认证的医疗生产线生产 全球统一的配方,提供全球一致性和供应链保 障 变更控制记录的不限于CAS编号级别,降低变 更风险 不含动物源性物质和邻苯二甲酸盐 标准母粒在PE载体中提供,可根据要求在PP 中提供 可以采用针对应用选择的特定树脂提供预着色 配方 • • • • • 药物类型 颜色说明 潘通色号参考 埃万特产品代码(PE基) 肾上腺素能激动剂组合 浅绿色 373 C PE6M176349 肾上腺素能激动剂 紫色 2583 C PE4M176057 抗感染药 棕褐色 467 C PE8M176130 非甾体类抗炎药 灰色 冷灰色 4 C PE7M176184 甾体类抗炎药 粉色 197 C PE3M176237 免疫调节剂类抗炎药 橄榄绿 5763 C 按要求提供 β-受体阻滞剂 黄色 黄色 C PE1M176160 β-受体阻滞剂组合 深蓝色 281 C PE5M176272 碳酸酐酶抑制剂 橘黄色 1585 C PE2M176089 细胞毒素 黑色 6 C PL9M176008 缩瞳剂 深绿色 348 C PE6M176267 散瞳剂和睫状肌麻痹剂 红色 1797 C PE3M176236 前列腺素类似物 绿松石 326 C PE5M176273 适用医疗保健使用限制—见下文。埃万特的产品不为以下目的或用途而设计,也不会宣传或预期用于以下目的或用途:(a) 被美国食品药品监督管理局(FDA)或国际标准化组织(ISO)归类为“植入”类器械的医疗器械;或美国药典(USP)或ISO标准定义的“永久”使用器械;或 (b) 经修订的欧盟指令90/385/EEC中定义的有源植入式医疗器械;或者 (c) 经修订的欧盟指令93/42/EEC中定义的“长期”使用的医疗器械。
https://www.avient.com/sites/default/files/2023-07/AVNT Q2 2023 Earnings Presentation%5B70%5D.pdf
AVIENT CORPORATION S E C O N D Q U A R T E R 2 0 2 3 R E S U L T S (NYSE: AVNT) J U L Y 2 7 , 2 0 2 3 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. GUIDANCE ( T O TA L C O M PA N Y ) 7 $845 $824 Guidance Actual $130 $131 Guidance Actual Sales Adjusted EBITDA (in millions) $0.60 $0.63 Guidance Actual Adjusted EPS (in millions) Q2 2023 PERFORMANCE VS. Avient reflects 2023 adjusted EBITDA guidance of $525M and estimated run-rate CAPEX of $110M. 2023E (%) 23 79 90 84 83 76 73 88 82 77 74 72 67 57 20 A vi e n t K W R P P G F U L A V Y R P M F M C C E H X L E C L A S H H U N E M N S C L Avient Specialty Formulators Other Specialty / Chemical Companies MULTI PL E EX PANSION Source: Peer data per Bloomberg as of 2023年7月21日 Note: Avient reflects 2023 adjusted EBITDA guidance of $525M and closing share price of $40.93.
https://www.avient.com/sites/default/files/2021-06/avient-ir-presentation-june-2021-w-non-gaap-recs_0.pdf
W H AT W E D O : M AT E R I A L S C I E N C E 4 CUSTOM FORMULATION We sell solutions not commodities. D is t. ) K W R R P M P P G A V Y F U L G C P H X L F M C F O E IF F H U N E C L A S H E M N K R A C E S C L G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of 2021年6月4日 Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 78% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of 2021年6月4日 87 89 87 86 83 81 76 88 85 83 82 81 80 78 78 78 76 72 71 69 50 18 A vi e n t K W R P P G R P M A V Y F U L G C P F M C H X L U N V R IF F E C L A S H F O E C E E M N B N R H U N G R A K R A S C L A L B Source: Peer data per Bloomberg market data as of 2021年6月4日 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers.